Advertisement
Advertisement
JAZZ
Jazz Pharmaceuticals, Inc.
236.49
USDSponsored
+1.11
+0.47%
May 29, 16:00 UTC -4
Closed
After-Market
236.45
-0.04
-0.02%
JAZZ Earnings Reports
Positive Surprise Ratio
JAZZ beat 23 of 42 last estimates.
55%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$1.14B
/$6.29
Implied change from Q1 26 (Revenue/ EPS)
+6.31%
/-0.79%
Implied change from Q2 25 (Revenue/ EPS)
+8.67%
/-176.24%
Jazz Pharmaceuticals, Inc. earnings per share and revenue
On May 05, 2026, JAZZ reported earnings of 6.34 USD per share (EPS) for Q1 26, beating the estimate of 4.65 USD, resulting in a 36.13% surprise. Revenue reached 1.07 billion, compared to an expected 996.09 million, with a 7.31% difference. The market reacted with a +7.68% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 9 analysts forecast an EPS of 6.29 USD, with revenue projected to reach 1.14 billion USD, implying an decrease of -0.79% EPS, and increase of 6.31% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Roivant Sciences Ltd. Common Shares
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.35
Actual
-$0.57
Surprise
-64.63%
Belite Bio, Inc - ADR
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.64
Actual
-$0.68
Surprise
-4.87%
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
May 22, 2026 For Q1 26
Estimate
-$1.53
Actual
-$2.35
Surprise
-53.05%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
OS Therapies Incorporated
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.27
Surprise
-49.83%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
EVOGENE LTD.
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.27
Actual
-$0.60
Surprise
-117.86%
FAQ
What were Jazz Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Jazz Pharmaceuticals, Inc. reported EPS of $6.34, beating estimates by 36.13%, and revenue of $1.07B, 7.31% above expectations.
How did the market react to Jazz Pharmaceuticals, Inc.'s Q1 2026 earnings?
The stock price moved up 7.68%, changed from $212.26 before the earnings release to $228.57 the day after.
When is Jazz Pharmaceuticals, Inc. expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for Jazz Pharmaceuticals, Inc.'s next earnings report?
Based on 9
analysts, Jazz Pharmaceuticals, Inc. is expected to report EPS of $6.29 and revenue of $1.14B for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement